Vandalia Research to Present at GTC 10th Vaccines R&D Conference
FOR IMMEDIATE RELEASE:
Huntington, W.Va. - Vandalia Research, Inc. announced today that Derek Gregg, CEO will make a presentation at the Global Technology Community's 10th Vaccines Research and Development: All Things Considered conference. The presentation will focus on the application of Triathlon™ large-scale polymerase chain reaction (PCR) DNA production technology for use in manufacturing linear expression cassette (LEC) DNA vaccines. Additionally, Dr. Michael Fons, President of Vandalia Vaccines, will present a poster regarding enhancing in vivo expression of linear expression cassettes.
GTC 10th Vaccines Research and Development: All Things Considered
July 9 - 10
San Francisco Airport Marriott Waterfront
1800 Old Bayshore Highway
Burlingame, CA 94010
Large-Scale Production System for Linear Expression Cassette DNA Vaccines
Monday, July 9 at 5:05 PM
Derek Gregg, CEO
Enhancement of In Vivo Expression of Linear Expression Cassettes
Monday, July 9 at 6:00 PM
Michael Fons, Ph.D., President, Vandalia Vaccines
About Vandalia Research, Inc.
Vandalia Research is the first company to successfully scale-up the polymerase chain reaction (PCR) from an analytical tool to a viable large-scale manufacturing process, enabling DNA sequences to be made more efficiently and cost-effectively. Vandalia is helping companies develop vaccines, diagnostics, bio-agriculture, and gene therapies for existing and emerging markets, and is well-positioned as a key supplier for the research, clinical, and commercialization stages of these products.